These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38182487)

  • 41. The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression.
    Pascale M; Azinwi CN; Marongiu B; Pesce G; Stoffel F; Roggero E
    BMC Cancer; 2017 Sep; 17(1):651. PubMed ID: 28923109
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    Carlson AS; Acevedo RI; Lim DM; Gulati R; Gawne A; Sokolova AO; Cheng HH; Nelson PS; Montgomery RB; Yu EY; Schweizer MT
    PLoS One; 2020; 15(9):e0239686. PubMed ID: 32997692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
    Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel.
    Nientiedt C; Endris V; Jenzer M; Mansour J; Sedehi NTP; Pecqueux C; Volckmar AL; Leichsenring J; Neumann O; Kirchner M; Hoveida S; Lantwin P; Kaltenecker K; Dieffenbacher S; Gasch C; Hofer L; Franke D; Tosev G; Görtz M; Schütz V; Radtke JP; Nyarangi-Dix J; Hatiboglu G; Simpfendörfer T; Schönberg G; Isaac S; Teber D; Koerber SA; Christofi G; Czink E; Kreuter R; Apostolidis L; Kratochwil C; Giesel F; Haberkorn U; Debus J; Sültmann H; Zschäbitz S; Jäger D; Duensing A; Schirmacher P; Grüllich C; Hohenfellner M; Stenzinger A; Duensing S
    Urol Oncol; 2020 Jul; 38(7):637.e17-637.e27. PubMed ID: 32280037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.
    Mayrhofer M; De Laere B; Whitington T; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Oeyen S; van Dam PJ; Van den Eynden G; Rutten A; Aly M; Nordström T; Van Laere S; Rantalainen M; Rajan P; Egevad L; Ullén A; Yachnin J; Dirix L; Grönberg H; Lindberg J
    Genome Med; 2018 Nov; 10(1):85. PubMed ID: 30458854
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutational analysis and clinical correlation of metastatic colorectal cancer.
    Russo AL; Borger DR; Szymonifka J; Ryan DP; Wo JY; Blaszkowsky LS; Kwak EL; Allen JN; Wadlow RC; Zhu AX; Murphy JE; Faris JE; Dias-Santagata D; Haigis KM; Ellisen LW; Iafrate AJ; Hong TS
    Cancer; 2014 May; 120(10):1482-90. PubMed ID: 24500602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutations in the AXIN1 gene in advanced prostate cancer.
    Yardy GW; Bicknell DC; Wilding JL; Bartlett S; Liu Y; Winney B; Turner GD; Brewster SF; Bodmer WF
    Eur Urol; 2009 Sep; 56(3):486-94. PubMed ID: 18514389
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations.
    Sztupinszki Z; Diossy M; Krzystanek M; Borcsok J; Pomerantz MM; Tisza V; Spisak S; Rusz O; Csabai I; Freedman ML; Szallasi Z
    Clin Cancer Res; 2020 Jun; 26(11):2673-2680. PubMed ID: 32071115
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.
    Kurnit KC; Kim GN; Fellman BM; Urbauer DL; Mills GB; Zhang W; Broaddus RR
    Mod Pathol; 2017 Jul; 30(7):1032-1041. PubMed ID: 28281553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC.
    Reifenberger J; Knobbe CB; Wolter M; Blaschke B; Schulte KW; Pietsch T; Ruzicka T; Reifenberger G
    Int J Cancer; 2002 Aug; 100(5):549-56. PubMed ID: 12124804
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
    J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer.
    Richau CS; Scherer NM; Matta BP; de Armas EM; de Barros Moreira FC; Bergmann A; Pereira Chaves CB; Boroni M; Dos Santos ACE; Moreira MAM
    Cancer Med; 2024 Feb; 13(3):e6729. PubMed ID: 38308422
    [TBL] [Abstract][Full Text] [Related]  

  • 54. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.
    Sutera P; Deek MP; Van der Eecken K; Shetty AC; Chang JH; Hodges T; Song Y; Verbeke S; Van Dorpe J; Fonteyne V; De Laere B; Mishra M; Rana Z; Molitoris J; Ferris M; Ross A; Schaeffer E; Roberts N; Song DY; DeWeese T; Pienta KJ; Antonarakis ES; Ost P; Tran PT
    Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1095-1101. PubMed ID: 36708787
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
    Abdi B; Basset N; Perrot E; Benderra MA; Khalil A; Oudard S; Blanchet P; Brureau L; Coulet F; Cussenot O; Cancel-Tassin G
    Prostate; 2022 Sep; 82(12):1196-1201. PubMed ID: 35652560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determinants of widespread metastases and of metastatic tropism in patients with prostate cancer: A genomic analysis of primary and metastatic tumors.
    Alshalalfa M; Goglia AG; Swami N; Nguyen B; Hougen HY; Khan A; Kishan AU; Punnen S; Nguyen PL; Mahal BA; Dee EC
    Urol Oncol; 2023 May; 41(5):253.e21-253.e26. PubMed ID: 37003878
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens.
    Nguyen PL; Haddad Z; Ross AE; Martin NE; Deheshi S; Lam LLC; Chelliserry J; Tosoian JJ; Lotan TL; Spratt DE; Stoyanova RS; Punnen S; Ong K; Buerki C; Aranes M; Kolisnik T; Margrave J; Yousefi K; Choeurng V; Davicioni E; Trock BJ; Kane CJ; Pollack A; Davis JW; Feng FY; Klein EA
    Eur Urol; 2017 Nov; 72(5):845-852. PubMed ID: 28528811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.
    Hoang T; Sutera P; Nguyen T; Chang J; Jagtap S; Song Y; Shetty AC; Chowdhury DD; Chan A; Carrieri FA; Hathout L; Ennis R; Jabbour SK; Parikh R; Molitoris J; Song DY; DeWeese T; Marchionni L; Ren L; Sawant A; Simone N; Lafargue A; Van Der Eecken K; Bunz F; Ost P; Tran PT; Deek MP
    Prostate; 2024 Jan; 84(1):87-99. PubMed ID: 37812042
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
    Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
    Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.